Cardiawave’s Valvosoft® Becomes the First Non-Invasive Treatment for Severe Symptomatic Aortic Stenosis to Receive CE Marking

Cardiawave has received CE Marking for Valvosoft®, the first non-invasive therapeutic alternative for Severe Symptomatic Aortic Stenosis (sSAS). 

This condition is a fast-growing degenerative disease linked to population ageing and remains without suitable treatment options for many patients worldwide, particularly those unable or unwilling to undergo immediate valve replacement.

Valvosoft® is based on Cardiawave’s Non-Invasive Ultrasound Therapy (NIUT) platform. The approval follows results from the company’s First-in-Man study and its Pivotal Study, which evaluated the therapy in 100 elderly, highly comorbid patients across 12 centres in four European countries. 

The studies reported feasibility, safety and durable clinical benefits at one year, including improved cardiac function and better quality of life.

Clinical experts involved in the studies noted strong safety performance and meaningful improvements in haemodynamic parameters in patients not eligible for immediate valve replacement. 

The results also point to the potential of NIUT to offer a new therapeutic pathway for individuals who previously had no viable treatment.

The CE Marking represents a major milestone for Cardiawave, signalling regulatory validation of this ultrasound-based approach and supporting broader adoption across Europe. 

The achievement highlights the growing role of non-invasive technologies in reshaping the management of aortic stenosis and wider cardiovascular disease, with further clinical progress in North America expected to be significant for future patient care.